Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is taking a unique and innovative physics-based approach to cancer treatment, giving the company a potential competitive edge. With promising early efficacy and safety data for their lead program NBTXR3, and ongoing trials for other indications, the company has a strong pipeline with potential for significant growth. However, the company also faces risks in clinical development, regulatory approvals, and commercialization, as well as potential financial risks and competition in the market. Overall, the unique approach and promising data suggest a positive outlook for Nanobiotix, but careful monitoring of potential risks will be important for investors.

Bears say

Nanobiotix is currently in the research and development stage, and although it has a promising innovative approach to cancer treatment, there is significant risk associated with their product candidates. Additionally, their limited pipeline and high cash burn rate indicate potential financial challenges in the future. Furthermore, even though their recent follow-on offering improved their cash position, it may not be enough to sustain their operations for its projected timeline, leading to a potential need for more financing.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.